De-escalating Management of N1b Papillary Thyroid Carcinoma: Are Total Thyroidectomy and RAI Mandatory for All?

MedXY Editorial Team•Dec 24, 2025•Diabetes & Endocrinology

No significant differences were observed in Recurrence-Free Survival (RFS) or Disease-Specific Survival (DSS) between patients undergoing lobectomy, total thyroidectomy, or total thyroidectomy followed by radioactive iodine (RAI) for cN1b papillary thyroid carcinoma.
The study suggests that the routine application of total thyroidectomy and adjuvant RAI in all patients with lateral neck metastasis may be unnecessary, particularly for those with lower-risk features.
Independent risk factors for shorter RFS included older age, larger primary tumor size, larger metastatic lymph node size, and the presence of extranodal extension (ENE).
Personalized surgical strategies may reduce treatment-related morbidity, such as permanent hypoparathyroidism and salivary gland dysfunction, without compromising oncologic safety.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

No significant differences were observed in Recurrence-Free Survival (RFS) or Disease-Specific Survival (DSS) between patients undergoing lobectomy, total thyroidectomy, or total thyroidectomy followed by radioactive iodine (RAI) for cN1b papillary thyroid carcinoma.
The study suggests that the routine application of total thyroidectomy and adjuvant RAI in all patients with lateral neck metastasis may be unnecessary, particularly for those with lower-risk features.
Independent risk factors for shorter RFS included older age, larger primary tumor size, larger metastatic lymph node size, and the presence of extranodal extension (ENE).
Personalized surgical strategies may reduce treatment-related morbidity, such as permanent hypoparathyroidism and salivary gland dysfunction, without compromising oncologic safety.